基底细胞癌中维莫德吉耐药：并非一帆风顺。
Vismodegib resistance in basal cell carcinoma: not a smooth fit.
机构信息
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, BRB 1053, 421 Curie Boulevard, Philadelphia, PA 19104, USA.
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, BRB 1053, 421 Curie Boulevard, Philadelphia, PA 19104, USA.
出版信息
Cancer Cell. 2015 Mar 9;27(3):315-6. doi: 10.1016/j.ccell.2015.02.009.
In this issue of Cancer Cell, two complementary papers by Atwood and colleagues and Sharpe and colleagues show that basal cell carcinomas resistant to the Smoothened (SMO) inhibitor vismodegib frequently harbor SMO mutations that limit drug binding, with mutations at some sites also increasing basal SMO activity.
在本期《癌细胞》中，Atwood 及其同事以及 Sharpe 及其同事的两篇互补论文表明，对 Smoothened（SMO）抑制剂 vismodegib 产生耐药性的基底细胞癌经常携带限制药物结合的 SMO 突变，一些位点的突变也会增加基底 SMO 活性。
Zotero 插件